UK markets open in 16 minutes
NIKKEI 225
38,556.87 -298.50 (-0.77%) HANG SENG
18,506.24 -314.92 (-1.67%) CRUDE OIL
80.14 +0.31 (+0.39%) GOLD FUTURES
2,353.50 -3.00 (-0.13%) DOW
38,852.86 -216.74 (-0.55%) Bitcoin GBP
53,663.66 +474.73 (+0.89%)
DCPH Oct 2024 17.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:31AM EDT. Market open.
| Previous close | 1.7300 |
| Open | 2.1000 |
| Bid | 0.1000 |
| Ask | 5.0000 |
| Strike | 17.50 |
| Expiry date | 2024-10-18 |
| Day's range | 1.7300 - 2.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 9 |
ZacksHere's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
While the top- and bottom-line numbers for Deciphera Pharmaceuticals (DCPH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
ZacksDeciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
Deciphera Pharmaceuticals (DCPH) delivered earnings and revenue surprises of 5.45% and 2.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksThe Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
© 2024 Yahoo. All rights reserved.